Hu Binwu, Shi Deyao, Lv Xiao, Wu Fashuai, Chen Songfeng, Shao Zengwu
Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,
Department of Orthopaedic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Onco Targets Ther. 2018 Aug 22;11:5083-5092. doi: 10.2147/OTT.S167355. eCollection 2018.
DEP domain containing mammalian target of rapamycin (mTOR)-interacting protein (DEPTOR), a recently discovered endogenous inhibitor of mTOR, has been found to be abnormally expressed in various tumors. Recent studies have demonstrated that DEPTOR could serve as a potential prognostic biomarker in several kinds of cancer. However, the prognostic value of DEPTOR is still controversial so far.
PubMed, Embase and Web of Science were systematically searched to obtain all relevant articles about the prognostic value of DEPTOR in cancer patients. ORs or HRs with corresponding 95% CIs were pooled to estimate the association between DEP-TOR expression and the clinicopathological characteristics or survival of cancer patients.
A total of nine eligible studies with 974 cancer patients were included in our meta-analysis. Our results demonstrated that the expression of DEPTOR was not associated with the overall survival (OS) (pooled HR=0.795, 95% CI=0.252-2.509) and event-free survival (EFS) (pooled HR=1.244, 95% CI=0.543-2.848) in cancer patients. Furthermore, subgroup analysis divided by sample size, type of cancer, Newcastle-Ottawa Scale (NOS) score and evaluation of DEPTOR expression showed identical prognostic value. In addition, our analysis also revealed that there was no significant association between expression level of DEPTOR and clinicopathological characteristics, such as tumor stage, lymph node metastasis, differentiation grade and gender.
Our meta-analysis suggested that despite the fact that DEPTOR could be overexpressed or downregulated in cancer patients, it might not be a potential marker to predict the prognosis of cancer patients.
含DEP结构域的哺乳动物雷帕霉素靶蛋白（mTOR）相互作用蛋白（DEPTOR）是最近发现的一种mTOR内源性抑制剂，已发现在多种肿瘤中异常表达。近期研究表明，DEPTOR可能是几种癌症潜在的预后生物标志物。然而，迄今为止，DEPTOR的预后价值仍存在争议。
系统检索PubMed、Embase和Web of Science，以获取所有关于DEPTOR在癌症患者中预后价值的相关文章。汇总具有相应95%置信区间的比值比（OR）或风险比（HR），以评估DEPTOR表达与癌症患者临床病理特征或生存之间的关联。
我们的荟萃分析共纳入9项符合条件的研究，涉及974例癌症患者。结果表明，DEPTOR的表达与癌症患者的总生存期（OS）（汇总HR = 0.795，95% CI = 0.252 - 2.509）和无事件生存期（EFS）（汇总HR = 1.244，95% CI = 0.543 - 2.848）无关。此外，按样本量、癌症类型、纽卡斯尔-渥太华量表（NOS）评分和DEPTOR表达评估进行的亚组分析显示出相同的预后价值。此外，我们的分析还表明，DEPTOR的表达水平与肿瘤分期、淋巴结转移、分化程度和性别等临床病理特征之间无显著关联。
我们的荟萃分析表明，尽管DEPTOR在癌症患者中可能出现过表达或低表达，但它可能不是预测癌症患者预后的潜在标志物。
